FY2017 EPS Estimates for Pfizer, Inc. Boosted by Leerink Swann (PFE)
Pfizer, Inc. (NYSE:PFE) – Research analysts at Leerink Swann raised their FY2017 earnings per share estimates for Pfizer in a note issued to investors on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings per share of $2.60 for the year, up from their prior estimate of $2.55. Leerink Swann also issued estimates for Pfizer’s FY2018 earnings at $2.66 EPS, FY2019 earnings at $2.70 EPS and FY2020 earnings at $2.73 EPS.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.61 earnings per share. TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/fy2017-eps-estimates-for-pfizer-inc-boosted-by-leerink-swann-pfe.html.
PFE has been the topic of a number of other reports. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reissued a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $38.35.
A number of institutional investors have recently modified their holdings of PFE. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer in the 2nd quarter worth $103,000. D. Scott Neal Inc. boosted its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC bought a new position in Pfizer in the 2nd quarter worth $120,000. Finally, Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer in the 1st quarter worth $121,000. 69.01% of the stock is owned by institutional investors.
In related news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 in the last ninety days. 0.06% of the stock is currently owned by insiders.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.